Genetics in Anti-Platelet Treatment

Title:Genetics in Anti-Platelet Treatment

Volume: 22 Issue: 29

Author(s): Maria Gazouli

Affiliation:

Keywords: Anti-platelet therapy, aspirin, ticagrelor, prasugrel, clopidogrel, GPIIb/IIIa inhibitors, acute coronary syndromes, cardiovascular disease, gene polymorphisms, miRNAs.

Abstract: Anti-platelet drugs are necessary in treating patients with coronary artery disease, ischemic stroke and peripheral arterial disease. However, despite the use of adequate anti-platelet therapy, some patients will experience a recurrent atherothrombotic vascular event. These patients are characterized as low- or non-responders to therapy. Individual responsiveness to anti-platelet therapy as the use of clopidogrel and/or aspirin varies widely among patients. Such an individual variability is mainly determined by environmental and genetic factors. In this review, we focused on the underlying genetic mechanisms that might influence response to anti-platelet drugs.

Cite this article as:

Gazouli Maria, Genetics in Anti-Platelet Treatment, Current Pharmaceutical Design 2016; 22 (29) . https://dx.doi.org/10.2174/1381612822666160601105058